Pulmonary disposition of tilmicosin in foals and in vitro activity against Rhodococcus equi and other common equine bacterial pathogens
Authors:
- 2 November 2006
- journal article
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
- Vol. 29 (6) , 561-568
Abstract
The objectives of this study were to determine the serum and pulmonary disposition of tilmicosin in foals and to investigate the in vitro activity of the drug against Rhodococcus equi and other common bacterial pathogens of horses. A single dose of a new fatty acid salt formulation of tilmicosin (10 mg/kg of body weight) was administered to seven healthy 5‐ to 8‐week‐old foals by the intramuscular route. Concentrations of tilmicosin were measured in serum, lung tissue, pulmonary epithelial lining fluid (PELF), bronchoalveolar lavage (BAL) cells, and blood neutrophils. Mean peak tilmicosin concentrations were significantly different between sampling sites with highest concentrations measured in blood neutrophils (66.01 ± 15.97 μg/mL) followed by BAL cells (20.1 ± 5.1 μg/mL), PELF (2.91 ± 1.15 μg/mL), lung tissue (1.90 ± 0.65 μg/mL), and serum (0.19 ± 0.09 μg/mL). Harmonic mean terminal half‐life in lung tissue (193.3 h) was significantly longer than that of PELF (73.3 h), bronchoalveolar cells (62.2 h), neutrophils (47.9 h), and serum (18.4 h). The MIC90 of 56 R. equi isolates was 32 μg/mL. Tilmicosin was active in vitro against most streptococci, Staphylococcus spp., Actinobacillus spp., and Pasteurella spp. The drug was not active against Enterococcus spp., Pseudomonas spp., and Enterobacteriaceae.Keywords
This publication has 33 references indexed in Scilit:
- A preliminary investigation of the disposition of tilmicosin residues in elk tissues and serumJournal of Veterinary Pharmacology and Therapeutics, 2004
- Retrospective Comparison of Azithromycin, Clarithromycin, and Erythromycin for the Treatment of Foals with Rhodococcus equi PneumoniaJournal of Veterinary Internal Medicine, 2004
- Pharmacokinetics of azithromycin in foals after i.v. and oral dose and disposition into phagocytesJournal of Veterinary Pharmacology and Therapeutics, 2002
- Pharmacokinetics of azithromycin and concentration in body fluids and bronchoalveolar cells in foalsAmerican Journal of Veterinary Research, 2001
- Uptake, Transport, and Delivery of Antimicrobial Agents by Human Polymorphonuclear NeutrophilsAntimicrobial Agents and Chemotherapy, 2001
- Pharmacokinetics and pharmacodynamics of tilmicosin in sheep and cattleJournal of Veterinary Pharmacology and Therapeutics, 1998
- Minimum Inhibitory Concentration Breakpoints and Disk Diffusion Inhibitory Zone Interpretive Criteria for Tilmicosin Susceptibility Testing against Pasteurella Spp. Associated with Bovine Respiratory DiseaseJournal of Veterinary Diagnostic Investigation, 1996
- Cardiovascular effects of the macrolide antibiotic tilmicosin, administered alone and in combination with propranolol or dobutamine, in conscious unrestrained dogsJournal of Veterinary Pharmacology and Therapeutics, 1996
- Tilmicosin antibacterial activity and pharmacokinetics in cowsJournal of Veterinary Pharmacology and Therapeutics, 1995
- Use of erythromycin-rifampin combination in treatment of Rhodococcus equi pneumoniaVeterinary Microbiology, 1987